MSH2 and cancer: If a reduction of MSH2 expression to 50% is sufficient to increase the rate of telomere shortening in normal differentiated tissues in vivo, then there would be an increased risk of early onset of telomere dysfunction leading to cellular senescence in heterozygous carriers that may affect tissue architecture and cancer progression35.